Neurophet

Focus: Neurophet is an AI-powered image processing biotech company headquartered in Seoul, South Korea, focused on developing neuromodulation and diagnostic solutions for neurological disorders. The company is publicly traded and operates at the intersection of artificial intelligence and neurology.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Neurophet

AI assessmentNot Hiring

No open roles listed right now. Follow Neurophet to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Optimized transcranial Direct Current Stimulation

Deglutition Disorders

N/A

Clinical Trials (1)

NCT06305949Clinical Trial on the Safety and Efficacy of Optimized Transcranial Direct Current Stimulation for the Swallowing Function in Patients With Post-Stroke Dysphagia

N/A

Help build intelligence for Neurophet

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Emerging AI-first biotech in high-value neurology space with five active programs spanning stroke, Alzheimer's, and Parkinson's disease
Public company status provides equity liquidity and potential for rapid scaling as pipeline advances
Positioned at the convergence of machine learning and neuromodulation, an underexploited therapeutic frontier

Watch Out For

Zero active job openings at time of assessment suggests potential hiring freeze or minimal expansion plans
Limited public pipeline clarity—all five programs show 'N/A' phase designations, making it difficult to assess clinical maturity and de-risking trajectory

Generated by Claude from Neurophet's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Neurophet SCALE PET

Alzheimer's Disease (AD)

N/A

Clinical Trials (1)

NCT07417540Evaluation of SCALE PET Software for Quantitative Brain PET Analysis in Alzheimer's Disease

N/A

High-Frequency, ipsilateral M1

Parkinson's Disease and Parkinsonism

N/A

Clinical Trials (1)

NCT06350617Personalized rTMS Protocol Based on Functional Reserve to Enhance Ambulatory Function in PD Patients

N/A

High-Frequency1

Stroke

N/A

Clinical Trials (1)

NCT06270238Efficacy of Personalized Repetitive Transcranial Magnetic Stimulation Protocol Based on Functional Reserve to Enhance Upper Limb Function in Subacute Stroke Patients

N/A

AI-based Customized transcranial Direct Current Stimulation

Subacute Stroke

N/A

Clinical Trials (1)

NCT07491029AI-based Customized tDCS for Finger Motor Recovery After Subacute Stroke

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

4 pipeline

Marketed

Pipeline